As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’
Archived version: https://archive.is/newest/https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead
Disclaimer: The article linked is from a single source with a single perspective. Make sure to cross-check information against multiple sources to get a comprehensive view on the situation.
“Oh, we can’t do that. We have to make back R&D costs and turn a nice profit for like a decade before other companies are allowed to produce a generic version. We’re literally going to capitalize on human suffering. Suck it.”
Only a decade? Buy off some politicians and you’ll be able to milk profits for a century. Just look at the price gouging fiesta pharma has had with insulin.